Tue.Sep 24, 2024

article thumbnail

Study Finds Ruxolitinib May Slow Fibrosis Progression in Myelofibrosis

Pharmacy Times

Researchers found that PF4/Cxcl4, a key driver of fibrosis, was up regulated on all proteomes.

145
145
article thumbnail

Opinion: Millions of people are missing from U.S. disability data

STAT

Many disabled people are not included in official U.S. data. This is because there is “ No Box to Check ” to indicate their particular disability on surveys from the U.S. Census Bureau and other federal agencies. The questions used to identify people with disabilities are missing millions. Two question sets are most often used to assess disability in U.S. federal surveys: the American Community Survey Six (ACS-6) or the Washington Group Short Set (WG-SS).

144
144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Women With Prior Knowledge of COVID-19 Vaccine More Likely Receive Vaccination While Pregnant

Pharmacy Times

Investigators reported that more than half of individuals had great knowledge about protecting themselves from COVID-19.

Vaccines 139
article thumbnail

STAT+: The U.S. has relied on cheap, effective generic drugs for 40 years. Now that promise is under threat

STAT

STAT is co-publishing this article by Tradeoffs. Lisa Ann Trainor struggled to stay on top of schoolwork, hold a job or even perform basic tasks like laundry for six exhausting years. Then, in 2018, she finally found a drug that kept her ADHD in check.

142
142
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Pomelo Care acquires the Doula Network to offer hybrid maternity care model

Fierce Healthcare

Pomelo Care, a value-based virtual provider of maternity care, has acquired the Doula Network, now offering virtual and in-person maternity care. | The acquisition expands the company’s reach to more than 15 million covered lives, including more than 1 in 6 Medicaid beneficiaries nationally.

132
132
article thumbnail

STAT+: Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices

STAT

WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of the treatments. It’s Sanders’ latest move to pressure Novo to cut the prices of the blockbuster diabetes and obesity therapies. Novo has been blaming pharmacy benefit managers for the high list prices of its drugs, arguing that it needs to be able to pay rebates to the middlemen i

132
132

More Trending

article thumbnail

STAT+: Baltimore claims Biogen ‘bribed’ PBMs to favor its pricey MS drug over generics

STAT

In the latest slap at a pharmaceutical company by a local government, the city of Baltimore has filed a lawsuit accusing Biogen of striking an “unlawful” scheme with the largest pharmacy benefit managers to block generic competition of a best-selling multiple sclerosis treatment. The effort allegedly originated as Biogen planned to fend off generic companies that hoped to sell lower-cost alternatives to Tecfidera which, several years ago, had been a franchise product and generated

article thumbnail

HHS watchdog flags potential remote monitoring fraud. Stakeholders say concerns about misuse are overblown

Fierce Healthcare

HHS OIG released an analysis of recent RPM claims data, flagging evidence of gaps in CMS oversight. Stakeholders say the report is hyperbolic.

130
130
article thumbnail

Getting Involved as a Pre-Pharmacy Student 

Pharmacy Is Right For Me

Hi Future Pharmacists! My name is Tazche Turner and I am a fourth year PharmD Candidate at the University of North Carolina’s (UNC) Eshelman School of Pharmacy. My passions for science, business and service led me to pursue a career in pharmacy. Throughout pharmacy school, I immersed myself into numerous organizations and leadership positions to really explore all pharmacy has to offer, but the organization I found my pharmacy home in was the Student National Pharmaceutical Association (SNPhA).

article thumbnail

CDC Expert Urges Equitable Vaccination of Children to Prevent Spread of Serious Disease

Pharmacy Times

Childhood immunization according to schedule can prevent serious illness.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Why climate change means more blood shortages: Q&A with HHS’ Rachel Levine

STAT

This summer, the American Red Cross declared an emergency blood shortage in the U.S. There’s a seasonal pattern to blood donations, which often dip over the summer and during the winter holidays. But experts also say that climate change disrupts the national blood supply, with extreme heat and worsening storms in certain regions keeping people away from blood banks.

129
129
article thumbnail

Novo Nordisk CEO prepares to defend Ozempic, Wegovy US pricing at Senate hearing

Fierce Pharma

After circling Novo Nordisk and its high GLP-1 drug prices for months, Sen. | Ahead of a hearing on Ozempic and Wegovy prices, prepared remarks from Novo CEO Lars Fruergaard Jørgensen shine a light on the larger U.S. healthcare system.

126
126
article thumbnail

STAT+: Amid push to redefine itself, Sanofi names new chief scientific officer

STAT

Sanofi named a new chief scientific officer this week, part of a series of moves that the drug company has argued will establish it as being more focused on research and development than in the past. In an internal memo obtained by STAT, Sanofi said Monday that it has named Mike Quigley, formerly the CEO of startups Dualitas Therapeutics and Therini Bio and senior vice president of research biology at Gilead, as its chief scientific officer and global head of research.

127
127
article thumbnail

CMS sets Medicaid renewal compliance deadlines

Fierce Healthcare

The feds have set new deadlines for compliance with Medicaid renewal requirements given widespread enrollment concerns during the unwinding. | The feds have set new deadlines for compliance with Medicaid renewal requirements given widespread enrollment concerns during the unwinding.

125
125
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy

Fierce Pharma

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply chain. | Vertex has inked a long-term supply agreement with Swiss CDMO Lonza to crank out global commercial supply of Casgevy. Under the deal, Lonza will produce Casgevy from its cell therapy manufacturing facilities in Geleen in the Netherlands and, eventually, its plant in Portsmouth, New Hampshire.

124
124
article thumbnail

“PBMs favour high list prices”- Novo Nordisk CEO targets PBMs in US Senate hearing

Pharmaceutical Technology

Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.

124
124
article thumbnail

Bluebird bio lays off 25% of workforce as gene therapy pioneer struggles to stay afloat

Fierce Pharma

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%. | After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%, or nearly 100 employees.

124
124
article thumbnail

FDA Accepts sNDA of Roflumilast Foam for Scalp and Body Psoriasis

Pharmacy Times

The FDA assigned a Prescription Drug User Fee Act action date of May 22, 2025.

FDA 123
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Mercy, Alice Walton philanthropies unveil $700M specialty care affiliation

Fierce Healthcare

Healthcare philanthropies and two major health systems have announced a 30-year, $700 million collaboration to grow value-based specialty and virtual care in Northwest Arkansas. | The collaboration, which also taps Cleveland Clinic expertise and branding, will develop specialty care centers of excellence with a focus on telehealth and value-based, whole person care.

122
122
article thumbnail

Dato-DXd Did Not Achieve Statistically Significant OS in Patients With Breast Cancer

Pharmacy Times

Compared with chemotherapy, datopotamab deruxtecan (Dato-DXd) did not achieve a statistically significant overall survival (OS) in patients with inoperable or metastatic HR+/HER2-low or negative breast cancer.

article thumbnail

STAT+: Amgen scores late-stage trial success for eczema and myasthenia gravis treatments, but faces stiff competition

STAT

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded in late-stage trials, but the therapies did not clearly beat existing competitors on the market. In the Phase 3 trials, dubbed Horizon and Mint, the California company tested therapies for eczema and myasthenia gravis, respectively.

article thumbnail

Ipsen crosses EU finish line with Alagille syndrome drug

pharmaphorum

After various twists and turns in the regulator path, Ipsen has secured EU approval for Kayfanda, its treatment for severe itching (pruritus) in patients with the rare liver disease Alagille syndrome (ALGS).Kayfanda (odevixibat) is labeled in the EU to treat cholestatic pruritus – itching caused by impaired bile formation or flow – in children aged six months and over with ALGS, a disease caused by a genetic mutation that leads to liver damage and jaundice.

Labelling 118
article thumbnail

STAT+: Novartis strikes AI drug development deal with Generate:Biomedicines

STAT

Generate:Biomedicines, a Flagship Pioneering company using artificial intelligence to create new medicines, announced today that it has struck a deal with Novartis to develop an undisclosed number of targets in various disease areas. With milestone payments, the company is eligible to receive over $1 billion, in addition to royalties. Novartis is paying Generate $65 million up front, which includes $15 million for an undisclosed amount of equity in the company.

117
117
article thumbnail

Contract manufacturer PCI pumps $365M+ into US, EU packaging projects

Fierce Pharma

Flush with new business, Philadelphia-based CDMO PCI Pharma Services is blueprinting multiple manufacturing outlays on both sides of the Atlantic. | PCI has “heavily invested” in new drug delivery tech at its Philadelphia headquarters, laid plans for a 545,000-square-foot expansion in Rockford, Illinois, acquired a new packaging and device assembly plant near Dublin, Ireland, and broken ground on another at its CityNorth Dublin campus.

Packaging 116
article thumbnail

Opinion: What happened when my mother became the first 2024 West Nile patient in Manhattan

STAT

What was that mosquito thinking as the six needles of its proboscis mouth bit into my mother’s skin? Had it taken a long, unplanned journey in a bag as a tourist traveled north from a tropical Caribbean island? Or was it an old-time New York mosquito that had feasted the night before on the sweaty skin of a feverish traveler from the south? My mother would remain incredulous at her bad luck: Why did this mosquito choose her arm to snack upon?

113
113
article thumbnail

Regeneron's stock drops as it loses bid to block Amgen's Eylea biosimilar

Fierce Pharma

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the c | Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the company’s attempt to block Amgen’s Eylea biosimilar.

115
115
article thumbnail

Voices in Pharmacy: September 2024 Expert Interviews

Drug Topics

Check out these featured Drug Topics interviews from September 2024.

112
112
article thumbnail

8 health benefits of kombucha

The Checkup by Singlecare

You might think you’re a health-conscious person, but how far does your commitment really go? Would you be willing to consume a drink brewed with something that looks and sounds like a high school science fair project to potentially improve your health? If you said yes, then keep reading. Kombucha is the beverage you get when you ferment tea with a SCOBY or a symbiotic culture of bacteria and yeast (in other words, a living, thriving colony of microorganisms…floating around in your tea).

article thumbnail

Podcast: PCMA on Drug Pricing, Transparency, and the Role of PBMs

Drug Topics

Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed the role his company plays in the ongoing issue of rising drug prices.

112
112
article thumbnail

AGC Biologics telegraphs layoffs, winds down production operations at Colorado plant

Fierce Pharma

As CDMOs across the industry continue to face pressure from a fluctuating biopharma business environment, AGC Biologics is charting another round of staff cuts and pumping the brakes at one of its | As part of the new restructuring push, AGC will lay off 68 employees at its cell and gene therapy plant in Longmont, Colorado, 17 employees at its commercial mammalian plant in Boulder, Colorado, and 10 employees in Bothell, Washington, according to a Worker Adjustment and Retraining Notification ale

111
111
article thumbnail

The Key to Personalized Care: Why Patient Segmentation Matters

PioneerRx

It's the people who make the job. From both sides of the pharmacy counter, your patients and pharmacy staff set the tone and tempo for your pharmacy operations.

111
111
article thumbnail

With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight

Fierce Pharma

When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit managers (PBMs) often commands at least some of the attention. | At the Senate committee hearing on Novo Nordisk's prices for Ozempic and Wegovy, debate around insurance coverage and pharmacy benefit managers took up much of the conversation.

Insurance 110
article thumbnail

Roche launches 'revolutionary' pathogen detection tech

pharmaphorum

Roche launches 12 in one test for respiratory virus, using its 'revolutionary' TAGS tech, that can be used in regular clinical labs

109
109